Publication

A glimpse into the future of model-informed drug discovery and development

Explore the future of Model-Informed Drug Development (MIDD), including advances in pharmacometrics, PBPK, QSP, precision…

CertaraAugust 28, 2026

Publication

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

Explore how model-based tumor growth inhibition metrics can support earlier Go/No-Go decisions and pivotal trial…

CertaraAugust 28, 2026

Case Study

De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)

Learn how Model-based meta-analysis (MBMA) helped optimize Phase 3 trial design, dose selection, and development…

Danielle PillsburyAugust 28, 2026

Blog

Medtech market access: why strategy can’t wait for regulatory approval

Medtech market access strategy must start long before approval. See how medical device reimbursement pathways…

Eduardo UrbinaAugust 26, 2026

Blog

Three CDISC standards are converging in 2026. Here’s how to stay ahead of it.

Three major CDISC standards are converging in 2026. Here's a practical framework for managing the…

Wendy YoungAugust 26, 2026

Fact Sheet

Model-Based Meta-Analysis (MBMA): Real-World Examples

See real-world examples of how model-based meta-analysis (MBMA) uses existing clinical evidence to predict trial…

CertaraAugust 24, 2026

Blog

MBMA data curation: How AI and expert meta-analysts get it right, fast

In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…

Matt Zierhut, PhD MBAAugust 14, 2026

White Paper

Managing drug-drug interaction (DDI) risk for patients in clinical trials

Discover how DIDB® helps clinical teams assess drug-drug interaction risk, develop prohibited medication lists, &…

Katie Owens, PhDAugust 12, 2026

Conference

EANM 2026

–

Danielle PillsburyJuly 20, 2026

Webinar

CHI Webinar: From Dosimetry to Dose Decisions How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development

Hunter Stephens, PhDJuly 17, 2026

Clinical Trials

A glimpse into the future of model-informed drug discovery and development

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)

Medtech market access: why strategy can’t wait for regulatory approval

Three CDISC standards are converging in 2026. Here’s how to stay ahead of it.

Model-Based Meta-Analysis (MBMA): Real-World Examples

MBMA data curation: How AI and expert meta-analysts get it right, fast

Managing drug-drug interaction (DDI) risk for patients in clinical trials

EANM 2026

CHI Webinar: From Dosimetry to Dose Decisions How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development

Newsletter sign up

Quick links

Solutions

Contact